<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">122041</article-id><article-id pub-id-type="doi">10.23868/202003005</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Nonmyeloablative bone marrow cells transplantation restores dystrophin synthesis in the muscles of MDX mice</article-title><trans-title-group xml:lang="ru"><trans-title>Немиелоаблативная трансплантация клеток костного мозга восстанавливает синтез дистрофина в мышцах мышей MDX</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sokolova</surname><given-names>A. V</given-names></name><name xml:lang="ru"><surname>Соколова</surname><given-names>А. В</given-names></name></name-alternatives><email>avsokolova@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Timonina</surname><given-names>NA. A</given-names></name><name xml:lang="ru"><surname>Тимонина</surname><given-names>Н. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kravtsova</surname><given-names>V. V</given-names></name><name xml:lang="ru"><surname>Кравцова</surname><given-names>В. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Krivoi</surname><given-names>I. I</given-names></name><name xml:lang="ru"><surname>Кривой</surname><given-names>И. И</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Skripkina</surname><given-names>N. S</given-names></name><name xml:lang="ru"><surname>Скрипкина</surname><given-names>Н. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kaminskaia</surname><given-names>E. V</given-names></name><name xml:lang="ru"><surname>Каминская</surname><given-names>Е. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mikhailov</surname><given-names>V. M</given-names></name><name xml:lang="ru"><surname>Михайлов</surname><given-names>В. М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Cytology Russian Academy of Science</institution></aff><aff><institution xml:lang="ru">Институт цитологии Российской академии наук</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Saint Petersburg State University</institution></aff><aff><institution xml:lang="ru">Санкт-Петербургский государственный университет</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">City clinical hospital № 31</institution></aff><aff><institution xml:lang="ru">Городская клиническая больница № 31</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-03-15" publication-format="electronic"><day>15</day><month>03</month><year>2020</year></pub-date><volume>15</volume><issue>1</issue><issue-title xml:lang="en">VOL 15, NO1 (2020)</issue-title><issue-title xml:lang="ru">ТОМ 15, №1 (2020)</issue-title><fpage>37</fpage><lpage>44</lpage><history><date date-type="received" iso-8601-date="2023-01-16"><day>16</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, Эко-Вектор</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/122041">https://genescells.ru/2313-1829/article/view/122041</self-uri><abstract xml:lang="en"><p>Duchenne muscular dystrophy is an X-linked recessive muscular dystrophy associated with a mutations in the dystrophin protein gene. The most common laboratory model of Duchenne muscular dystrophy is mdx mice. The striated muscle fibers of mdx mice are characterized by the absence of dystrophin, the presence of centrally located nuclei, and the high level of renewal of the striated muscle fibers. In addition, mdx mice show a morphological aberrations at neuromuscular junctions, expressed in the breakdown of large clusters of acetylcholine receptors in the form of branches into small clusters in the form of islets. One approach to treating muscular dystrophy in mdx mice may be the nonmyeloablative transplantation of wild-type bone marrow cells after X-ray irradiation of mdx mice at a dose of 3 Gy. The aim of this work is to evaluate the effect of nonmyeloabla-tive transplantation of wild-type bone marrow cells on dystrophin synthesis and the structure of neuromuscular junctions of mdx mice. Mdx mice were irradiated with X-rays at a dose of 3 Gy, after 24 hours was performed intravenous transplantation of bone marrow cells of C57BL/6 mice. The m. quariceps femoris and diaphragm were examined 2, 4, 6, 9, 12 months after transplantation. Muscle studies were performed using immunohisto-chemical methods of study (immunohistochemical staining with antibodies to dystrophin). The neuromuscular junctions were stained with tetramethylrodamine-a-bungarotoxin. After intravenous bone marrow cells transplantation, the part of dystrophin-positive muscle fibers in the muscle quadriceps femoris was shown to increase to a 27,6±6,7% 6 months after transplantation. After 12 months, the part of dystrophin-positive muscle fibers decreased to 5,1±1,1%. There was also an increase in the proportion of striated muscle fibers without centrally located nuclei and a decrease in the part of dead striated muscle fibers. Similar changes were found in the striated muscle fibers of the diaphragm of mdx mice. In addition, transplantation of bone marrow cells after irradiation at a dose of 3 Gy increases the part of neuromuscular junctions with normal structure. Thus, nonmy-eloablative transplantation of wild-type bone marrow cells can be considered as one way to treat monogenic disease of striated muscle fibers muscular dystrophy of mdx mice.</p></abstract><trans-abstract xml:lang="ru"><p>Мышечная дистрофия Дюшенна - Х-сцепленная рецессивная мышечная дистрофия, связанная с мутациями в гене белка дистрофина. Наиболее распространенной лабораторной моделью мышечной дистрофии Дюшенна являются мыши mdx. Для поперечнополосатых мышечных волокон мышей mdx характерно отсутствие дистрофина, наличие центрально расположенных ядер в волокнах, а также высокий уровень обновления поперечнополосатых мышечных волокон. Кроме того, у мышей mdx наблюдается нарушение структуры нейромышечных соединений, выражающееся в распаде больших кластеров ацетилхолиновых рецепторов, имеющих форму ветвей, на мелкие кластеры, имеющие форму островков. Цель работы - оценить влияние немиелоаблативной трансплантации клеток костного мозга мышей «дикого» типа C57BL/6 на синтез дистрофина и структуру нейромышечных соединений у мышей mdx. Через 1 сутки после рентгеновского облучения в немиелоблативной дозе 3 Гр мышам mdx внутривенно трансплантировали клетки костного мозга мышей C57BL/6. Через 2, 4, 6, 9 и 12 мес. после трансплантации на гистологических препаратах четырехглавой мышцы бедра и диафрагмы методом имммуногистохимии по окраске антителами к дистрофину определяли количество дистрофин-положительных мышечных волокон, погибших волокон и волокон, не имеющих центрально расположенных ядер. Нейромышечные соединения окрашивали тетраметилродамин-а-бунгаротоксином. Было показано увеличение количества дистрофин-положительных мышечных волокон в четырехглавой мышце бедра до 27,6±6,7% через 6 мес. после трансплантации и их снижение до 5,1±1,1% через 12 мес., а также увеличение количества поперечнополосатых мышечных волокон, не имеющих центрально расположенных ядер, и уменьшение количества погибших мышечных волокон. Аналогичные изменения были обнаружены в поперечнополосатых мышечных волокнах диафрагмы мышей mdx. Кроме того, после трансплантации клеток костного мозга увеличивалось количество нейромышечных соединений с нормальной структурой. Таким образом, немиелоаблативная трансплантация клеток костного мозга мышей «дикого» типа может рассматриваться как один из способов лечения моногенного заболевания - мышечной дистрофии у мышей mdx.</p></trans-abstract><kwd-group xml:lang="en"><kwd>cell therapy</kwd><kwd>bone marrow cells</kwd><kwd>striated muscle fibers</kwd><kwd>dystrophin</kwd><kwd>mdx mice</kwd><kwd>neuromuscular junctions</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>клеточная терапия</kwd><kwd>клетки костного мозга</kwd><kwd>поперечнополосатые мышечные волокна</kwd><kwd>дистрофин</kwd><kwd>мыши mdx</kwd><kwd>нейромышечные соединения</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Min Y.L., Bassel-Duby R., Olson E.N. CRISPR Correction of Duchenne Muscular Dystrophy. Ann. Rev. Med. 2019; 70: 239-55.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Collins C.A., Morgan J.E. Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies. Int. J. Exp. Pathol. 2003; 84(4): 165-72.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Dalkilic I., Kunkel L.M. Muscular dystrophies: genes to pathogenesis. Curr. Opin. Genet. Dev. 2003; 13(3): 231-8.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Otto A., Coolins-Hooper H., Patel K. The origin, molecurlar regulation and therapeutic potencial of myogenic stem cell populations. J. of Anatomy 2009; 215: 477-97.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Negroni E., Gidaro T., Bigot A. et al. Stem cells and muscle diseases: advances in cell therapy strategies. J. Neuropathology and Applied Neurobiology 2015; 41: 270-87.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Hoffman E.P., Brown R.H. Jr., Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51(6): 919-28.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Зайнитдинова М.И., Смирнихина С.А., Лавров А.В. и др. Геннотерапевтические подходы к лечению миодистрофии Дюшенна. Гены &amp; Клетки 2019; XIV(4): 6-18.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bulfield G., Siller W.G., Wight P.A. et al. X chromosome-linked muscular dystrophy (mdx) in the mouse. PNAS USA 1984; 81(4): 1189-92.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Sicinski P., Geng Y., Ryder-Cook A.S. et al. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989; 244(4912): 1578-80.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kong J., Anderson J.E. Dystrophin is required for organizing large acetylcholine receptor aggregates. Brain Res. 1999; 839(2): 298-304.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Minatel E., Neto H.S., Marques M.J. Acetylcholine receptors and neuronal nitric oxide synthase distribution at the neuromuscular junction of regenerated muscle fibers. Muscle Nerve 2001; 24: 410-6.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Marques M.J., Pertille A., Carvalho C.L. et al. Acetylcholine receptor organization at the dystrophic extraocular muscle neuromuscular junction. Anat. Rec. (Hoboken) 2007; 290(7): 846-54.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Соколова А.В., Зенин В.В., Михайлов В.М. Структура нейро-мышечных соединений и дифференцировка поперечно-полосатых мышечных волокон у мышей mdx после клеточной терапии стволовыми клетками костного мозга. Цитология 2010; 52(5): 399-406.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Quaеttrocelli M., Cassano M., Crippa S. et al. Cell therapy strategies and improvements for muscular dystrophy. Cell Death and Differentiation 2010; 17: 1222-9.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Wilschut K.J., Ling V.B., Bernstein H.S. Concise Review: Stem cell therapy for muscular dystrophies. Stem Cells Translational medicine 2012; 1(11): 833-42.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Partridge T.A., Morgan J.E., Coulton G.R. et al. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 1989; 337: 176-9.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Siemionow M., Cwykiel J., Heydemann A. et al. Dystrophin expressing chimeric (DEC) human cells provide a potencial therapy for Duchenne muscular therapy. Stem Cell Reviews and reports 2018; 14: 370-84.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Gussoni E., Soneoka Y., Strickland C.D. et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999; 401(6751): 390-4.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Bittner R.E., Schofer C., Weipoltshammer K. et al. Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anat. Embryol. (Berl.) 1999; 199(5): 391-6.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>De Angelis L., Berghella L., Coletta M. et al. Skeletal Myogenic progenitors originating from embryonic dorsal aorta coexpress endothelial and myogenic markers and contribute to postnatal muscle growth and regeneration. The Journal of Cell Biology 1999; 147(4): 869-77.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Torrente Y., Belicchi M., Sampaolesi M. et al. Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J. Clin. Invest. 2004; 114: 182-95.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Peault B., Rudnicki M., Torrente Y. et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol. Ther. 2007; 15(5): 867-77.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Galvez B.G., Sampaolesi M., Brunelli S. et al. Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability. J. Cell Biol. 2006; 174(2): 231-43.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Dellavalle A., Sampaolesi M., Tonlorenzi R. et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat. Cell Biol. 2007; 9(3): 255-67.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Farini A., Razini P., Erratico S. et al. Cell based therapy for Duchenne muscular dystrophy. J. Cell. Physiol. 2009; 221(3): 526-34.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Szade K., Gulati G.S., Chan C.K.F. et al. Where hematopoietic stem cells live: The bone marrow niche. Antioxid. Redox Signal. 2018; 29(2): 191-204.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Asahara T., Murohara T. Sullivan A. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Kataoka K., Medina R.J., Kageyama T. et al. Participation of adult mouse bone marrow cells in reconstitution of skin. Am. J. Pathol. 2003; 163(4): 1227-31.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Kale S., Karihaloo A., Clark P.R. et al. Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J. Clin. Invest. 2003; 112(1): 42-9.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Hess D., Li L., Martin M. et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat. Biotechnol. 2003L; 21(7): 763-70.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Mezey E., Chandross K.J. Bone marrow: a possible alternative source of cells in the adult nervous system. Eur. J. Pharmacol. 2000; 405(1-3): 297-302.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Mikhailov V.M. Life cycle of decidual cells. In: Jeon K.W., editor. A survey of cell biology. San Diego: Academic Press (an Elsevier Imprint); 2003. p. 2-63.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Mikhailov V.M., Sokolova A.V., Serikov V.B. et al. Bone marrow stem cells repopulate thyroid regeneration in mice. Pathophysiology 2012; 19: 5-11.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Alawadhi F., Du H., Cakmak H. et al. Bone Marrow-Derived Stem Cell (BMDSC) transplantation improves fertility in a murine model of Asher-man's syndrome. PLoS One 2014; 9(5): e96662.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Ferrari G., Cusella-De Angelis G., Coletta M. et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279(5356): 1528-30.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>LaBarge M.A., Blau H.M. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell 2002; 111(4): 589-601.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Dreyfus P.A., Chretien F., Chazaud B. et al. Adult bone marrow-derived stem cells in muscle connective tissue and satellite cell niches. Am. J. Pathol. 2004; 164(3): 773-9.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Михайлов В.М., Евтифеева Е.В., Сериков В.Б. и др. Участие стволовых клеток костного мозга в дифференцировке поперечнополосатых мышц мышей mdx. Цитология 2006; 48(5): 410-7.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Wernig G., Jansen V., Schafer R. et al. The vast majority of bone-marrow-derived cells integrated into mdx muscle fibers are silent despite long-term engraftment.PNAS USA 2005; 102(33): 11852-7.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Соколова А.В., Соколов Г.В., Михайлов В.М. Слабое комбинированное магнитное поле, настроенное на ион-параметрический резонанс для Ca2+, интенсифицирует синтез дистрофина в скелетных мышцах мышей mdx после клеточной терапии. Цитология 2016; 58 (2):150-5.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Lucarelli G., Isgro A., Sodani P. et al. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb. Perspect. Med. 2012; 2(5): a011825.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Hsieh M.M. A standard nonmyeloablative transplantation regimen for adults with sickle cell disease: Are we there Yet? Biol. blood marrow transplantation 2016; 22: 397-9.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Полак Дж., Ван Норден С. Введение в иммуноцитохимию: современные методы и проблемы: Пер. с англ. Москва [СССР]: Мир; 1987</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Marques M.J., Taniguti A.P., Minatel E. et al. Nerve terminal contributes to acetylcholine receptor organization at the dystrophic neuromuscular junction of mdx mice. Anat. Rec. (Hoboken) 2007; 290(2): 181-7.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Кравцова В.В., Михайлов В.М., Соколова А.В. и др. Восстановление электрогенеза скелетной мышцы после клеточной терапии миодистрофии у мышей mdx. Доклады Академии наук 2011; 441(2): 272-4.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Mikhailov V.M., Sokolova A.V., Kravtsova V.V. et al. Non-myeloablative bone marrow stem cell transplantation for mdx mice myodystrophy therapy. J. Cell Sci. Ther. 2012; 3: 122.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Соколова А.В. Усиление синтеза дистрофина и улучшение структуры нейромышечных соединений мутантных мышей mdx после трансплантации клеток костного мозга. В: Яблонский П.К., главный редактор. Фундам. наука клин. мед. Материалы XVI Всероссийской медико-биологической конференции молодых ученых (с международным участием); 2013 апрель 20; Санкт-Петербург, Россия. Санкт-Петербург: Издательский дом СПбГУ; 2013. стр. 379-80.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Тимонина Н.А., Кравцова В.В., Михайлова Е.В. и др. Электрогенез концевых пластинок диафрагмы мышей mdx: эффект клеточной терапии. Вестник СПбГУ Сер. 3. 201 5; 3: 66-74</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Andrade J., Ge S., Symbatyan G. et al. Effects of sublethal irradiation on patterns of engraftment after murine bone marrow transplantation. Biol. Blood Marrow Transplant. 2011; 17(5): 608-19.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Haddix S.G., Lee Y.I., Kornegay J.N. et al. Cycles of myofiber degeneration and regeneration lead to remodeling of the neuromuscular junction in two mammalian models of Duchenne muscular dystrophy. PLoS One 2018; 13(10): e0205926.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Rafael J.A., Townsend E.R., Squire S.E. et al. Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure. Hum. Mol. Genet. 2000; 9: 1357-67.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Banks G.B., Chamberlain J.S., Froehner S.C. Truncated dystrophins can influence neuromuscular synapse structure. Mol. Cell. Neurosci. 2009; 40: 433-41.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Kong J., Yang L., Li Q. et al. The absence of dystrophin rather than muscle degeneration causes acetylcholine receptor cluster defects in dystrophic muscle. Neuroreport 2012; 23(2): 82-7.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>McClive P.J., Huang D., Morahan G. C57BL/6 and C57BL/10 inbred mouse strains differ at multiple loci on chromosome 4. Immunogenetics 1994; 39: 286-8.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Kennelly K.P., Holmes T.M., Wallace D.M. et al. Early subretinal allograft rejection is characterized by innate immune activity. Cell Transplant. 2017; 26(6): 983-1000.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Sampaolesi M., Blot S., D'Antona G. et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006; 444(7119): 574-9.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>van Putten M., Hulsker M., Young C. et al. Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/ utrophin double-knockout mice. FASEB J. 2013; 27(6): 2484-95.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>van der Pijl E.M., van Putten M., Niks E.H. et al. Low dystrophin levels are insufficient to normalize the neuromuscular synaptic abnormalities of mdx mice. Neuromuscul. Disord. 2018; 28(5): 427-42.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Wells D.J. What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy? J. Muscle Res. Cell Motil. 2019; 40(2): 141-50.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Ozdogu H., Boga C. Hematopoietic stem cell transplantation in adult sickle cell disease: problems and solution. Turk. J. Haematol. 2015; 32(3): 195-205.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Pietzner J., Baer P.C., Duecker R.P. et al. Bone marrow transplantation improves the outcome of Atm-deficient mice through the migration of ANM-competent cells. Human mol. Genetics 2013, 22(3): 493-507</mixed-citation></ref></ref-list></back></article>
